Dr. Yaxiong Zhang is currently an attending doctor in the Department of Medical Oncology at Sun Yat-Sen University (SYSU) Cancer Center, Guangzhou, China. He mainly focuses on basic and clinical research of lung cancer. He has published more than 50 SCI-indexed papers in JNCI, Journal of Thoracic Oncology, Molecular cancer, Journal for ImmunoTherapy of Cancer, The Oncologist, Clinical Lung Cancer and other specialty periodical. Besides, he has won IASLC APLCC-Travel Grant Award and given poster presentation in ASCO, ESMO ESMO Asia and APLCC for many times.

Mainly focuses on basic and clinical research of lung cancer and nasopharyngeal carcinoma and support care in cancer. 2009-2017, Zhongshan School of Medicine, Sun Yat-sen University, M.D.

1. Zhang Y, Chang L, Yang Y, Fang W, Guan Y, Wu A, Hong S, Zhou H, Chen G, Chen X et al: Intratumor heterogeneity comparison among different subtypes of non-small-cell lung cancer through multi-region tissue and matched ctDNA sequencing. Molecular cancer 2019, 18(1):7.

2. Zhang Y, Chang L, Yang Y, Fang W, Guan Y, Wu A, Hong S, Zhou H, Chen G, Chen X et al: The correlations of tumor mutational burden among single-region tissue, multi-region tissues and blood in non-small cell lung cancer. Journal for immunotherapy of cancer 2019, 7(1):98.

3. Zhang Y, Chang L, Fang W, Yang Y, Zhang L, Hong S, Zhou H, Guan Y, Yi X, Zhang L: Preferable background filtering for next-generation sequencing analysis in non-small cell lung cancer: pericarcinomatous tissues or peripheral blood lymphocytes? Cancer Communications (London, England) 2019, 39(1):33.

4. Zhang Z, Zhang Y, Chen G, Hong S, Yang Y, Fang W, Luo F, Chen X, Ma Y, Zhao Y et al: Olanzapine-Based Triple Regimens Versus Neurokinin-1 Receptor Antagonist-Based Triple Regimens in Preventing Chemotherapy-Induced Nausea and Vomiting Associated with Highly Emetogenic Chemotherapy: A Network Meta-Analysis. The oncologist 2018, 23(5):603-616.

5. Zhang Y, Zhou H, Zhang L: Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1? Journal for immunotherapy of cancer 2018, 6(1):135.

6. Zhang Y, Zhang Z, Huang X, Kang S, Chen G, Wu M, Miao S, Huang Y, Zhao H, Zhang L: Therapeutic Efficacy Comparison of 5 Major EGFR-TKIs in Advanced EGFR-positive Non-Small-cell Lung Cancer: A Network Meta-analysis Based on Head-to-Head Trials. Clinical lung cancer 2017, 18(5):e333-e340.

7. Zhang Y, Yang Y, Zhang Z, Fang W, Kang S, Luo Y, Sheng J, Zhan J, Hong S, Huang Y et al: Neurokinin-1 Receptor Antagonist-Based Triple Regimens in Preventing Chemotherapy-Induced Nausea and Vomiting: A Network Meta-Analysis. Journal of the National Cancer Institute 2017, 109(2).

Updated by International Office, Sun Yat-sen University Cancer Center